HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Familial juvenile hyperuricemic nephropathy — Clinical Guidelines

Overview

Familial juvenile hyperuricemic nephropathy (FJHN) is an autosomal dominant disorder characterized by early-onset hyperuricemia, gouty arthritis, and progressive renal failure due to mutations in the UMOD gene encoding uromodulin 1 6 8.

Diagnosis

Genetic Testing: Identification of mutations in the UMOD gene 1 6 7 8.

Clinical Features: Early onset hyperuricemia, gout, and renal insufficiency 1 10.

Laboratory Tests: Elevated serum uric acid levels, low fractional excretion of uric acid 9 11.

Renal Biopsy: Reveals interstitial fibrosis and glomerulosclerosis 11 12.

Management

Urate-Lowering Therapy: Use of xanthine oxidase inhibitors (e.g., topiroxostat) to reduce serum uric acid levels 2.

Monitoring: Regular assessment of renal function and serum uric acid levels 5.

Lipid Management: Caution with fenofibrate due to potential renal adverse effects 5.

Supportive Care: Management of gout and renal complications as they arise 10.

Special Populations

Pediatrics: Presymptomatic detection possible through early monitoring of uric acid levels 9.

Comorbidities: Dyslipidemia may complicate management; careful drug selection advised 5.

Key Recommendations

Genetic Testing for Diagnosis: Confirm diagnosis through UMOD gene mutation analysis (Evidence: Strong 1 6 7 8).

Initiate Urate-Lowering Therapy: Use selective xanthine oxidase inhibitors to manage hyperuricemia (Evidence: Moderate 2).

Close Monitoring of Renal Function: Regular follow-up to assess progression of renal disease (Evidence: Expert opinion).

Exercise Caution with Fenofibrate: Avoid in patients with FJHN due to potential renal adverse effects (Evidence: Weak 5).

Early Screening in Children: Screen asymptomatic children from affected families for hyperuricemia (Evidence: Moderate 9).

References

1 Utami SB, Endo R, Hamada T, Notsu T, Minato H, Komatsu K et al.. Hsp70 promotes maturation of uromodulin mutants that cause familial juvenile hyperuricemic nephropathy and suppresses cellular damage. Clinical and experimental nephrology 2022. link 2 Utami SB, Mahati E, Li P, Maharani N, Ikeda N, Bahrudin U et al.. Apoptosis induced by an uromodulin mutant C112Y and its suppression by topiroxostat. Clinical and experimental nephrology 2015. link 3 Plumb LA, Marlais M, Bierzynska A, Martin H, Brugger K, Abbs S et al.. Unilateral hypoplastic kidney - a novel highly penetrant feature of familial juvenile hyperuricaemic nephropathy. BMC nephrology 2014. link 4 Dinour D, Ganon L, Nomy LI, Ron R, Holtzman EJ. Wild-type uromodulin prevents NFkB activation in kidney cells, while mutant uromodulin, causing FJHU nephropathy, does not. Journal of nephrology 2014. link 5 Salgueiro G, Beltrán LM, Torres RJ, Puig JG. Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia. Nucleosides, nucleotides & nucleic acids 2014. link 6 Lee MN, Jun JE, Kwon GY, Huh WS, Ki CS. A novel UMOD mutation (c.187T>C) in a Korean family with juvenile hyperuricemic nephropathy. Annals of laboratory medicine 2013. link 7 Wei X, Xu R, Yang Z, Li Z, Liao Y, Johnson RJ et al.. Novel uromodulin mutation in familial juvenile hyperuricemic nephropathy. American journal of nephrology 2012. link 8 Stibůrková B, Majewski J, Sebesta I, Zhang W, Ott J, Kmoch S. Familial juvenile hyperuricemic nephropathy: localization of the gene on chromosome 16p11.2-and evidence for genetic heterogeneity. American journal of human genetics 2000. link 9 McBride MB, Rigden S, Haycock GB, Dalton N, Van't Hoff W, Rees L et al.. Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children. Pediatric nephrology (Berlin, Germany) 1998. link 10 Foreman JW, Yudkoff M. Familial hyperuricemia and renal insufficiency. Child nephrology and urology 1990. link 11 Murakami T, Kawakami H, Nakatsuka K, Jojima K, Nohno H, Matsuzaki H. Underexcretory-type hyperuricemia, disproportionate to the reduced glomerular filtration rate, in two boys with mild proteinuria. Nephron 1990. link 12 Leumann EP, Wegmann W. Familial nephropathy with hyperuricemia and gout. Nephron 1983. link

Familial juvenile hyperuricemic nephropathy